AbstractBackground Research on the efficacy of first-line osimertinib in non-small cell lung cancer (NSCLC) patients with different epidermal growth factor receptor (EGFR) exon 19 deletion (19del) mutation sites is limited. This study aimed to evaluate whether different EGFR 19del subtypes...
Abstract EGFR and HER2 are overexpressed in numerous malignancies, including breast cancer. A novel series of 1,2,3-triazole hybrids comprising quinoline-imidazole moieties was created as part of an ongoing endeavor to find new anticancer drugs targeting these proteins. Several analytical techniques,...
Osimertinib Combo Boosts PFS in EGFR/TP53+ NSCLC Trial Data from the phase 3 TOP trial support a potential molecular risk–guided treatment strategy for EGFR-mutant advanced NSCLC. Data from the phase 3 TOP trial (NCT04695925) demonstrated a significant progression-free survival (PFS)...
The humanization of mouse monoclonal antibodies targeting tumor antigens allows for the safe and repeated administration of therapeutic antibodies to humans. Previously, we reported on mouse monoclonal antibody 40H3 and its reactivity with a conformational epitope exposed on EGFR when...
Abstract Health technology assessments (HTAs) for targeted therapies like osimertinib require models capturing individual pharmacokinetic/pharmacodynamic (PK/PD) variability in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). Traditional models often fail to reflect these dynamics adequately. This study compared...
Dr Girard on Updated Data From the PALOMA-2 Trial in EGFR-Mutant NSCLC Nicolas Girard, MD, PhD, discusses updated data from the phase 2 PALOMA-2 trial (NCT05498428) that were presented at the 2026 European Lung Cancer Congress. “The results are [relatively]...
Sac-TMT Extends OS in Pretreated EGFR-Mutated NSCLC Sac-TMT offered significant survival benefits vs docetaxel in pretreated EGFR-mutated NSCLC. The TROP2-directed antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) displayed a significant overall survival (OS) benefit compared with docetaxel in patients with pretreated EGFR-mutated...
Health-Related Quality of Life in Patients Previously Treated With an EGFR-TKI From HARMONi: A Phase 3 Trial of Ivonescimab vs Placebo Plus Chemotherapy Published on 03/27/2026 at 12:28 pm EDT Publicnow Share SUMMIT THERAPEUTICS INC. -4.17% Health-Related Quality of Life...
Sacituzumab Tirumotecan Improves Survival in EGFR-Mutant NSCLC: Final OS from OptiTROP-Lung03 Patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) face limited treatment options after progression on EGFR tyrosine kinase inhibitors (TKIs) and platinum-based chemotherapy. Outcomes in this setting remain...
